328 related articles for article (PubMed ID: 28277310)
21. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).
Pelayo-Terán JM; Gajardo Galán VG; de la Ortiz-García de la Foz V; Martínez-García O; Tabarés-Seisdedos R; Crespo-Facorro B; Ayesa-Arriola R
Eur Arch Psychiatry Clin Neurosci; 2017 Jun; 267(4):315-323. PubMed ID: 27796500
[TBL] [Abstract][Full Text] [Related]
22. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.
Bowtell M; Ratheesh A; McGorry P; Killackey E; O'Donoghue B
Schizophr Res; 2018 Jul; 197():9-18. PubMed ID: 29146020
[TBL] [Abstract][Full Text] [Related]
23. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
24. Frequency and predictive values of first rank symptoms at baseline among 362 young adult patients with first-episode schizophrenia Results from the Danish OPUS study.
Thorup A; Petersen L; Jeppesen P; Nordentoft M
Schizophr Res; 2007 Dec; 97(1-3):60-7. PubMed ID: 17698323
[TBL] [Abstract][Full Text] [Related]
25. Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi: A STROBE-compliant article.
Kaminga AC; Dai W; Liu A; Myaba J; Banda R; Wen SW; Pan X
Medicine (Baltimore); 2018 Nov; 97(45):e13078. PubMed ID: 30407306
[TBL] [Abstract][Full Text] [Related]
26. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
[TBL] [Abstract][Full Text] [Related]
27. The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication.
Di Capite S; Upthegrove R; Mallikarjun P
Early Interv Psychiatry; 2018 Oct; 12(5):893-899. PubMed ID: 27734591
[TBL] [Abstract][Full Text] [Related]
28. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia.
Klærke LR; Baandrup L; Fagerlund B; Ebdrup BH; Pantelis C; Glenthøj BY; Nielsen MØ
Eur Psychiatry; 2019 Oct; 62():130-137. PubMed ID: 31614250
[TBL] [Abstract][Full Text] [Related]
30. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
[TBL] [Abstract][Full Text] [Related]
31. Predictors of symptomatic remission in first-episode psychosis outpatients treated with quetiapine: a naturalistic study.
Gade K; Köhler J; Klein P; Falkai P; Wobrock T
Int J Psychiatry Clin Pract; 2013 Jun; 17(2):148-53. PubMed ID: 22746987
[TBL] [Abstract][Full Text] [Related]
32. You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication.
Zipursky RB; Odejayi G; Agid O; Remington G
Schizophr Res; 2020 Nov; 225():39-46. PubMed ID: 32115315
[TBL] [Abstract][Full Text] [Related]
33. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Caseiro O; Martínez-Garcia O; Pardo G; Ramirez-Bonilla M; Pelayo-Terán JM; Vázquez-Barquero JL
J Psychiatr Res; 2011 Jun; 45(6):763-9. PubMed ID: 21106207
[TBL] [Abstract][Full Text] [Related]
34. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10years after baseline: The OPUS study.
Bergh S; Hjorthøj C; Sørensen HJ; Fagerlund B; Austin S; Secher RG; Jepsen JR; Nordentoft M
Schizophr Res; 2016 Aug; 175(1-3):57-63. PubMed ID: 27050475
[TBL] [Abstract][Full Text] [Related]
35. Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: a first-episode psychosis study.
Tang JY; Chang WC; Hui CL; Wong GH; Chan SK; Lee EH; Yeung WS; Wong CK; Tang WN; Chan WF; Pang EP; Tso S; Ng RM; Hung SF; Dunn EL; Sham PC; Chen EY
Schizophr Res; 2014 Mar; 153(1-3):1-8. PubMed ID: 24529612
[TBL] [Abstract][Full Text] [Related]
36. When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?
Zhang T; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Xie B; Li C; Wang J
Aust N Z J Psychiatry; 2021 Mar; 55(3):314-323. PubMed ID: 33143440
[TBL] [Abstract][Full Text] [Related]
37. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort.
Austin SF; Mors O; Budtz-Jørgensen E; Secher RG; Hjorthøj CR; Bertelsen M; Jeppesen P; Petersen L; Thorup A; Nordentoft M
Schizophr Res; 2015 Oct; 168(1-2):84-91. PubMed ID: 26265299
[TBL] [Abstract][Full Text] [Related]
38. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.
Schoeler T; Petros N; Di Forti M; Klamerus E; Foglia E; Murray R; Bhattacharyya S
Lancet Psychiatry; 2017 Aug; 4(8):627-633. PubMed ID: 28705600
[TBL] [Abstract][Full Text] [Related]
39. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
[TBL] [Abstract][Full Text] [Related]
40. Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index.
Haring L; Koido K; Vasar V; Leping V; Zilmer K; Zilmer M; Vasar E
Schizophr Res; 2015 Dec; 169(1-3):22-29. PubMed ID: 26364730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
